Northland Capital Markets Downgrades Amarin Corporation (AMRN) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P stumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Amarin Corporation (AMRN) PT Lowered to $9 at Cowen
May 4, 2022 12:55 PM EDTCowen analyst Ken Cacciatore lowered the price target on Amarin Corporation (NASDAQ: AMRN) to $9.00 (from $10.00) while maintaining an Outperform rating.
The analyst commented, "Q1 sales were $94MM, coming in well below the Street. We continue to question the ongoing... More
Amarin Corp. (AMRN) Misses Q1 EPS by 6c
May 4, 2022 7:04 AM EDTAmarin Corp. (NASDAQ: AMRN) reported Q1 EPS of ($0.08), $0.06 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $94.63 million versus the consensus estimate of $128.37 million.
For earnings history and earnings-related data on Amarin Corp. (AMRN) click here.
... MoreAmarin Corp. (AMRN) Reports New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction
May 3, 2022 8:12 AM EDTAmarin Corporation plc (NASDAQ: AMRN) today announced the publication in the Journal of the American College of Cardiology (JACC) of a new REDUCE-IT® data analysis further strengthening evidence of the benefits of icosapent ethyl in adult patients most at risk of suffering from a potentially fatal or non-fatal cardiovascular (CV) event. This new sub-analysis was led by Deepak L. Bhatt, M.D., M.P.H., Brigham and Womens Hospital, Harvard Medical School, Boston, MA.
The patients identified in the new REDUCE-IT sub-analysis had experienced a prior myocardial infarction (MI),... More
